⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65108 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL7285171 | 0.69 | — | — | |
| Methane SCHEMBL27872321 | 0.69 | — | — | |
| SCHEMBL27150056 | 0.69 | — | — | |
| SCHEMBL7715835 | 0.69 | — | — | |
| Iodide SCHEMBL27655122 | 0.69 | — | — | |
| SCHEMBL25769095 | 0.67 | — | — | |
| SCHEMBL11068278 | 0.67 | — | — | |
| SCHEMBL214214 | 0.67 | — | — | |
| SCHEMBL6962823 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855476-A2 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2015-04-08 | — | — | EP | claimed |
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | claimed |
| WO-2013181579-A2 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2013-12-05 | — | — | WO | claimed |
| EP-2280978-B1 | PYRROLIDINE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-04-24 | — | — | EP | claimed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | claimed |
| US-8119628-B2 | Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | claimed |
| EP-2280981-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | claimed |
| EP-2280978-A1 | PYRROLIDINE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | claimed |
| US-20110020276-A1 | Pyrrolidine Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | claimed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | claimed |
| WO-2009120733-A1 | PYRROLIDINE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-01 | — | — | WO | claimed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | claimed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2280978-B1 | PYRROLIDINE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-6916815-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004054514-A2 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-01 | — | — | WO | disclosed |
| US-4415566-A | ANTIBIOTICS; BACTERIOSTATS; BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DE) | 1983-11-15 | — | — | US | disclosed |